Kathy Boltz, PhD

Most Recent Articles by Kathy Boltz, PhD

High tumor immune cell levels may identify women with HER2+ breast cancer who may benefit from chemotherapy alone

Women with HER2-positive breast cancer who had higher levels of immune cells in their tumors showed a lower risk of cancer recurrence after treatment with chemotherapy alone.

Adding pictilisib to fulvestrant may benefit advanced ER/PR+ breast cancer

In women with aromatase inhibitor-resistant, advanced or metastatic breast cancer positive for both estrogen receptor (ER) and progesterone receptor (PR), adding pictilisib (previously GDC-0941) to the endocrine therapeutic fulvestrant increased survival.

Adding ovarian suppression to tamoxifen reduced recurrence for some premenopausal breast cancer

Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.

Tamoxifen found to lower breast cancer rates among high-risk women in trial

The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.

Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer

Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.

More Articles by Kathy Boltz, PhD

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs